POP Seminar Guest Speaker Announcement: Dr. Wei-Hsuan Jenny Lo Ciganic

The UF College of Pharmacy Department of Pharmaceutical Outcomes and Policy welcomes Dr. Wei-Hsuan Jenny Lo-Ciganic as our December 1st, 2017 Guest Speaker for POP Seminar.

Wei-Hsuan Jenny Lo-Ciganic, Ph.D., MSCP, M.S., is an Assistant Professor at the University of Arizona College of Pharmacy, Department of Pharmacy Practice and Science. She is a pharmacoepidemiologist with research interests in drug safety, medication adherence, prescription drug abuse and pain management, quality and value of prescribing, and application of advanced analytics.

She was a recipient of the 2015 University of Arizona Health Science (UAHS) Career Development Award, which focused on the use of survival trees and random survival forests to predict prescription opioid misuse among patients with lower back pain and osteoarthritis.

She was also a recipient of the 2016 American Association of College of Pharmacy New Investigator Award to examine longitudinal adherence trajectories of new hepatitis C therapies.

In addition, she is a recipient of the 2017 Pharmaceutical Research and Manufacturers of America (PhRMA) Foundation Research Starter Award in Health Outcomes to apply advanced analytics and develop prediction tools for identifying patients and regions at risk of problematic opioid use in Medicare.

More recently, she is the Co-PI for the R01 project funded by the National Institute of Drug Abuse (NIDA), “Using Machine Learning to Predict Problematic Opioid Use”, in two large state Medicaid programs.

Since 2015, she has been a member and co-chair of Pharmacy Quality Alliance’s (PQA) workgroups to develop quality measures on opioid use and adherence to hepatitis C therapy.

She also serves on the National Committee for Quality Assurance (NCQA) Opioid and Pain Management Expert Panel.

She has continued contributing her expertise to numerous multi-disciplinary collaborations on pharmacoepidemiologic and health services research in the Pennsylvania Medicaid program, the largest population-based case-control study of ovarian cancer in the U.S. (i.e., Hormone and Ovarian Cancer Prediction Study), the Ovarian Cancer Association Consortium (with over 50 sites involved worldwide), Healthy Aging and Body Composition Study, Osteoarthritis Initiative Study and the studies conducted in the CDC Prevention Research Center for Healthy Aging in Pittsburgh.